Trial Profile
A longitudinal HR-pQCT (high-resolution peripheral quantitative computed tomography) study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2011
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 14 Mar 2011 New trial record